GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population

被引:21
作者
Chatzimichalis, M. [3 ]
Xenellis, J. [2 ]
Tzagaroulakis, A. [2 ]
Sarof, P. [3 ]
Banis, K. [3 ]
Gazouli, M. [1 ]
Bibas, A. [2 ]
机构
[1] Univ Athens, Dept Biol, Sch Med, Athens 11527, Greece
[2] Univ Athens, Dept Otolaryngol Head & Neck Surg, Athens 11527, Greece
[3] Metaxa Anticancer Hosp, Dept Otolaryngol Head & Neck Surg, Piraeus, Greece
关键词
Laryngeal Squamous Cell Carcinoma; Gene Polymorphisms; GSTT1; GSTM1; GSTM3; NAT2; GLUTATHIONE-S-TRANSFERASE; LUNG-CANCER RISK; GENETIC POLYMORPHISMS; NECK; HEAD; M1; ACETYLTRANSFERASES; SUSCEPTIBILITY; EPIDEMIOLOGY; ACETYLATION;
D O I
10.1017/S002221510999154X
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objective: It is well known that laryngeal squamous cell carcinoma is strongly related to tobacco and alcohol consumption. Accumulating evidence suggests that alterations of detoxification enzymes, such as glutathione S-transferases and N-acetyltransferases, influence the risk of cancers associated with tobacco smoke and alcohol. Methods: This was a retrospective case control study. The study group consisted of 88 Greek patients with laryngeal squamous cell carcinoma; there were also 1102 control subjects. Frequencies of the genotypes GSTT1, GSTM1, GSTM3 and NAT2 were evaluated by polymerase chain reaction restriction fragment polymorphism. Results: The distribution of overall genotypes was 55.68 per cent rapid acetylator and 44.32 per cent slow acetylator in patients, and 36.27 per cent rapid acetylator and 63.72 per cent slow acetylator in controls. The odds ratio for rapid acetylator status in cases versus controls was 2.207 (95 per cent confidence interval 1.23-3.95, p = 0.0087). Conclusion: This study demonstrated a significant relationship between rapid acetylator genotypes and laryngeal squamous cell carcinoma in a Greek population.
引用
收藏
页码:318 / 323
页数:6
相关论文
共 22 条
  • [1] MOLECULAR MECHANISM OF SLOW ACETYLATION OF DRUGS AND CARCINOGENS IN HUMANS
    BLUM, M
    DEMIERRE, A
    GRANT, DM
    HEIM, M
    MEYER, UA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (12) : 5237 - 5241
  • [2] Pharmacogenetics of the arylamine N-acetyltransferases
    Butcher N.J.
    Boukouvala S.
    Sim E.
    Minchin R.F.
    [J]. The Pharmacogenomics Journal, 2002, 2 (1) : 30 - 42
  • [3] CANN CI, 1985, OTOLARYNG CLIN N AM, V18, P367
  • [4] Pitfalls in N-acetyltransferase 2 genotyping
    Cascorbi, I
    Roots, I
    [J]. PHARMACOGENETICS, 1999, 9 (01): : 123 - 127
  • [5] CASORBI I, 1996, CANCER RES, V56, P3961
  • [6] DETERMINATION OF HUMAN NAT2 ACETYLATOR GENOTYPE BY RESTRICTION-FRAGMENT-LENGTH-POLYMORPHISM AND ALLELE-SPECIFIC AMPLIFICATION
    DOLL, MA
    FRETLAND, AJ
    DEITZ, AC
    HEIN, DW
    [J]. ANALYTICAL BIOCHEMISTRY, 1995, 231 (02) : 413 - 420
  • [7] DROZDZ M, 1987, NEOPLASMA, V34, P481
  • [8] Glutathione S-transferase M1 polymorphism and lung cancer risk in African-Americans
    Ford, JG
    Li, YL
    O'Sullivan, MM
    Demopoulos, R
    Garte, S
    Taioli, E
    Brandt-Rauf, PW
    [J]. CARCINOGENESIS, 2000, 21 (11) : 1971 - 1975
  • [9] CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma
    Gajecka, M
    Rydzanicz, M
    Jaskula-Sztul, R
    Kujawski, M
    Szyfter, W
    Szyfter, K
    [J]. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 574 (1-2) : 112 - 123
  • [10] METABOLIC-ACTIVATION AND DEACTIVATION OF ARYLAMINE CARCINOGENS BY RECOMBINANT HUMAN NAT1 AND POLYMORPHIC NAT2 ACETYLTRANSFERASES
    HEIN, DW
    DOLL, MA
    RUSTAN, TD
    GRAY, K
    FENG, Y
    FERGUSON, RJ
    GRANT, DM
    [J]. CARCINOGENESIS, 1993, 14 (08) : 1633 - 1638